N
0.866
0.00 (0.44%)
| Previous Close | 0.862 |
| Open | 0.880 |
| Volume | 327,603 |
| Avg. Volume (3M) | 265,742 |
| Market Cap | 109,380,232 |
| Price / Book | 0.610 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2025 |
| Diluted EPS (TTM) | -0.540 |
| Total Debt/Equity (MRQ) | 15.09% |
| Current Ratio (MRQ) | 17.36 |
| Operating Cash Flow (TTM) | -56.82 M |
| Levered Free Cash Flow (TTM) | -34.19 M |
| Return on Assets (TTM) | -19.06% |
| Return on Equity (TTM) | -30.93% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Nautilus Biotechnology, Inc. | Mixed | Bearish |
AIStockmoo Score
-0.8
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.83 |
|
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 33.38% |
| % Held by Institutions | 48.76% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ah Capital Management, L.L.C. | 30 Jun 2025 | 17,653,917 |
| Madrona Venture Group, Llc | 30 Jun 2025 | 6,020,770 |
| Clarius Group, Llc | 30 Jun 2025 | 1,060,460 |
| Tikvah Management Llc | 30 Jun 2025 | 726,895 |
| Archpoint Investors | 30 Jun 2025 | 622,409 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 07 Oct 2025 | Announcement | Nautilus Biotechnology to Announce Third Quarter 2025 Financial Results on October 28, 2025 |
| 16 Sep 2025 | Announcement | Presenting at the Investor Summit Q3 2025 on September 16; Watch the Live Stream for Free |
| 27 Aug 2025 | Announcement | Nautilus Biotechnology to Participate in Upcoming September Investor Conferences |
| 31 Jul 2025 | Announcement | Nautilus Biotechnology Reports Second Quarter 2025 Financial Results |
| 30 Jul 2025 | Announcement | Nautilus Biotechnology Announces Agreement with the Allen Institute, Further Validating its Approach to Single-Molecule Proteomics |
| 15 Jul 2025 | Announcement | Nautilus Biotechnology to Announce Second Quarter 2025 Financial Results on July 31, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |